Key takeaways
- Studies show that 15% to 40% of weight lost on GLP-1 drugs comes from lean muscle mass rather than fat.
- A clinical advisory recommends consuming 1.2 to 1.6 grams of protein per kilogram of body weight daily to preserve muscle.
- Experts recommend a minimum of 90 minutes of weekly resistance training and monthly body composition scans during active treatment.
What happened
Medical experts are warning that up to 40% of the weight lost by patients taking blockbusters like Ozempic, Wegovy, Mounjaro, and Zepbound actually comes from lean muscle mass rather than stored body fat. According to clinical data and obesity specialists interviewed by MedPage Today on September 14, 2026, this significant rate of muscle depletion is prompting a major shift in how telehealth providers and cash-paying patients must manage their treatment. To combat this issue, clinicians are advising patients to closely track their body composition, significantly increase their protein intake, and commit to structured resistance training.
Why it matters
For the millions of Americans purchasing GLP-1 medications online through telehealth platforms, this clinical reality completely changes the definition of "successful" weight loss. Simply watching the number on a standard bathroom scale drop is no longer sufficient; rapid weight loss without proper monitoring can severely compromise metabolic health, strength, and long-term physical function.
Muscle loss is exceptionally difficult to reverse once it occurs, making it a critical concern for postmenopausal women, older adults over age 65, sedentary individuals, and people with a history of weight cycling. This development means that US buyers looking at online providers must evaluate whether a telehealth platform merely writes a prescription or if it also offers the comprehensive nutritional guidance, fitness planning, and body composition tracking tools necessary to prevent severe muscle wasting.
What the data says
While GLP-1 receptor agonists are highly effective—frequently driving overall weight loss of up to 20%—the underlying change in body composition can be stark. According to medical experts cited by MedPage Today:
- Lean Mass Loss Rates: Studies estimate that between 15% and 40% of GLP-1-induced weight loss consists of lean body mass.
- The Semaglutide Difference: A recent observational study utilizing advanced dual-energy X-ray absorptiometry (DEXA) scans revealed that adults taking semaglutide (Wegovy) lost 47.5% of their weight as lean mass. By comparison, those using only diet and lifestyle interventions lost 35.7% as lean mass.
- The Protein Target: A joint clinical advisory from four medical organizations recommends a daily protein intake target of 1.2 to 1.6 grams per kilogram of body weight during active weight loss. For a 200-pound (90.7 kg) adult, that equates to roughly 109 to 145 grams of protein per day.
- Resistance Training Minimums: Experts state that a minimum of two dedicated resistance-training sessions per week is a "non-negotiable" requirement, with a clinical goal of progressing toward at least 90 minutes of weekly strength training using progressive overload.
How it compares
In the competitive telehealth market, some online clinics simply facilitate a quick medical intake and mail a vial of compounded semaglutide or tirzepatide, leaving the consumer to navigate nutrition on their own. However, managing muscle preservation requires active clinical intervention.
Because GLP-1 drugs suppress appetite, consuming 100+ grams of protein daily can be incredibly difficult. Clinicians recommend prioritizing protein first at every meal, followed by vegetables, and leaving starches for last. Some premium telehealth providers are beginning to bundle digital body composition scales (which use bioelectrical impedance to measure fat versus skeletal muscle mass) into their monthly subscriptions, or recommending that patients get scans monthly during active weight loss and every 4 to 6 months during maintenance.
If a patient continues to lose muscle at an undesirable rate despite proper diet and exercise, clinicians may have to slow down the medication's dose escalation, lower the dose, or temporarily pause treatment altogether—a level of hands-on medical care that cheap, "subscription-only" telehealth platforms rarely provide.
How this fits the bigger picture
This focus on muscle preservation highlights why the weight-loss industry is moving away from treating GLP-1s as simple "magic bullets." As highlighted by UCSF researchers in our previous coverage, treating obesity solely as a biological issue that can be medicated away ignores the broader lifestyle and dietary infrastructure required for long-term health, as discussed in our article on UCSF researchers warning that GLP-1s are no magic bullet.
Furthermore, because muscle loss and other side effects can make the treatment journey physically demanding, it sheds light on why a substantial portion of patients struggle to stay on the medications long-term. As we explored when analyzing Danish registry data, nearly half of Wegovy patients quit within a year. To improve these retention rates, online buyers are increasingly seeking providers on platforms like CompareRx that offer robust clinical support systems, rather than just medication delivery.
What happens next
As awareness of GLP-1-induced muscle loss grows, both pharmaceutical manufacturers and telehealth companies are adapting. We can expect online weight-loss platforms to increasingly integrate companion apps, virtual coaching, and smart scales into their monthly cash-pay bundles to help patients track lean mass.
Additionally, drugmakers are actively investigating next-generation compounds designed to be paired with GLP-1s to preserve or even build muscle during rapid fat loss. Until those therapies reach the market, the responsibility falls on patients and their telehealth clinicians to prioritize protein, lift weights, and monitor body composition closely.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare professional before starting, stopping, or altering any medical treatment or weight-loss regimen.